Sitryx is supported by an international syndicate of world-class healthcare investors.

Sitryx Investors

Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. In 2023 the Company welcomed new investor Oxford Science Enterprises following the successful completion of an additional financing, raising a further $39 million.

Our collaboration with Lilly

In 2020 Sitryx formed an exclusive global licensing and research collaboration with Eli Lilly and Company. Lilly also became an investor in the company.

  • $60mUpfront payment and equity investment
  • Up to $1.1bnPotential development and commercial milestones in addition to tiered royalties